- Home
- AFCG vs KZIA Comparison
AFCG vs KZIA Comparison
Compare AFCG & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AFCG | KZIA |
|---|---|---|
| Founded | 2020 | 1994 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 87.8M | 100.8M |
| IPO Year | 2020 | 2002 |
Fundamental Metrics
Financial Performance| Metric | AFCG | KZIA |
|---|---|---|
| Price | $3.33 | $14.08 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | $4.50 | ★ $19.50 |
| AVG Volume (30 Days) | 173.8K | ★ 206.0K |
| Earning Date | 05-07-2026 | 06-04-2026 |
| Dividend Yield | ★ 6.94% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.49 | N/A |
| Revenue | ★ $24,563,601.00 | N/A |
| Revenue This Year | $1,334.03 | N/A |
| Revenue Next Year | $17.33 | N/A |
| P/E Ratio | $6.98 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.06 | $4.86 |
| 52 Week High | $5.10 | $17.40 |
Technical Indicators
Market Signals| Indicator | AFCG | KZIA |
|---|---|---|
| Relative Strength Index (RSI) | 47.18 | 60.79 |
| Support Level | $3.20 | $5.62 |
| Resistance Level | $3.37 | $14.57 |
| Average True Range (ATR) | 0.15 | 1.09 |
| MACD | -0.06 | 0.14 |
| Stochastic Oscillator | 3.70 | 75.80 |
Price Performance
Historical ComparisonAbout AFCG AFC Gamma Inc.
Advanced Flower Capital Inc is an externally managed Maryland corporation that operates as a Business Development Company (BDC). The firm's primary operations involve originating, structuring, underwriting, and managing senior secured loans and other debt securities. Its investment portfolio includes loans to state law-compliant cannabis operators, ancillary cannabis businesses, and middle-market companies in other industries. These loans are typically secured by collateral such as real estate, equipment, cash flows, and license values.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.